細胞再程式化市場：依產品分類

預計到2026年，細胞再程式化市場規模將達到4.371億美元，2033年將達到7.887億美元。預計從2026年到2033年，該市場將以8.8%的複合年成長率成長。

全球細胞再程式化市場是再生醫學和生物技術領域的創新前沿，從根本上改變了研究人員和臨床醫生進行細胞治療和疾病治療的方式。細胞再程式化是將分化細胞恢復到多功能狀態或直接將其轉化為其他細胞類型的過程，它正逐漸成為一項基礎性技術，帶來前所未有的治療可能性。這種先進的生物學方法涵蓋多種調查方法，包括誘導性多功能幹細胞細胞（iPS細胞）的建構、直接再程式化和轉分化過程，每種方法在個人化醫療應用中都具有獨特的優勢。

該市場涵蓋了研究工具、試劑、儀器和服務等一系列完整的生態系統，旨在促進全球學術機構、製藥公司和生物技術公司進行細胞再程式化。隨著精準醫療和再生醫學的日益普及，細胞再程式化技術正被擴大整合到藥物研發流程、疾病建模平台以及針對以往無法治癒疾病的潛在治療性介入中。先進的基因編輯技術、改進的再程式化方案以及對細胞可塑性機制的深入理解，使該市場處於下一代醫療創新的前沿，有望重塑多個治療領域的治療模式。

市場動態

全球細胞再程式化市場受多種強勁因素驅動，這些因素共同支撐著其穩健的成長動能。慢性病、遺傳性疾病和老齡化相關疾病的日益普遍，催生了對創新療法的巨大需求，而細胞再程式化技術恰好能夠滿足這些需求。再生醫學研發投入的增加，以及政府的扶持性資助舉措和有利的法規結構，正顯著加速市場發展。再程式化調查方法的技術進步，包括非整合方法和化學成分明確的方案，在提高效率的同時降低了安全隱患，從而擴大了商業性可行性。

製藥業對個人化醫療和患者特異性治療方案的日益重視，推動了基於誘導多能幹細胞（iPSC）的藥物篩檢和毒性測試平台的應用。然而，市場成長仍面臨許多限制因素，包括細胞療法複雜的監管流程、實現穩定重編程效率的巨大技術挑戰，以及建構專業實驗室基礎設施的高昂成本。幹細胞研究相關的倫理考量，以及重編程方案標準化程度不足，進一步阻礙了市場進入。重編程細胞的基因組不穩定性及其致瘤潛能引發的安全性擔憂，也持續構成監管和商業上的挑戰。儘管如此，新的機會蘊藏著巨大的成長潛力，尤其是在疾病建模、加速藥物研發以及開發現成細胞療法等方面的應用拓展。生物技術公司與大型製藥公司之間的策略合作，有助於技術轉移和商業化。新興市場對iPSC的日益普及，以及人們對再生醫學益處的認知不斷提高，正在為行業相關人員創造新的收入來源和市場拓展機會。

本研究的關鍵特徵

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究基於以下參數分析了全球細胞再程式化市場的主要參與者：公司亮點、產品系列、關鍵亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 全球細胞再程式化市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過分析全球細胞再程式化市場中使用的各種策略矩陣輕鬆做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球細胞再程式化市場：依產品分類，2021-2033年

• 裝置
• 耗材及試劑盒（再程式化試劑盒、培養基及試劑、生長因子、培養容器等）
• 軟體（細胞分析軟體、資料管理平台、流程控制軟體）
• 服務（再程式化服務、細胞株開發、品管測試）

第5章 全球細胞再程式化市場：依細胞類型分類，2021-2033年

• 體細胞
• 胚胎幹細胞
• 成體幹細胞
• 癌症幹細胞
• 間質幹細胞

第6章 全球細胞再程式化市場：依細胞來源分類，2021-2033年

• 人類細胞
• 動物細胞

第7章 全球細胞再程式化市場：依技術分類，2021-2033年

• 利用仙台病毒再程式化
• mRNA再程式化
• 附加體重編程
• 基於小分子的再程式化
• 利用 CRISPR 或 Cas9再程式化
• 其他再程式化技術

第8章 全球細胞再程式化市場：依應用領域分類，2021-2033年

• 幹細胞研究
• 疾病模型
• 毒性測試
• 藥物篩檢
• 再生醫學

第9章 全球細胞再程式化市場：依最終用戶分類，2021-2033年

• 製藥和生物技術公司
• 醫院和診所
• 受託研究機構（CRO）
• 政府和非營利組織
• 其他（學術/研究機構等）

第10章 全球細胞再程式化市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第11章 競爭格局

• Thermo Fisher Scientific
• Merck KGaA
• Takara Bio Inc
• Lonza Group
• FUJIFILM Cellular Dynamics
• StemCell Technologies
• REPROCELL Inc
• Astellas Pharma
• Fate Therapeutics
• Cynata Therapeutics
• Pluri Inc
• ViaCyte Inc
• BlueRock Therapeutics
• Century Therapeutics
• Editas Medicine

第12章 分析師建議

• 機會分析
• 分析師意見
• 一致的機會地圖

第13章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Cell Reprogramming Market is estimated to be valued at USD 437.1 Mn in 2026 and is expected to reach USD 788.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033.

The global cell reprogramming market represents a revolutionary frontier in regenerative medicine and biotechnology, fundamentally transforming how researchers and clinicians approach cellular therapy and disease treatment. Cell reprogramming, the process of converting differentiated cells back to a pluripotent state or directly into other cell types, has emerged as a cornerstone technology enabling unprecedented therapeutic possibilities. This sophisticated biological technique encompasses various methodologies including induced pluripotent stem cell (iPSC) generation, direct reprogramming, and trans differentiation processes, each offering unique advantages for personalized medicine applications.

The market encompasses a comprehensive ecosystem of research tools, reagents, instruments, and services that facilitate cellular reprogramming across academic institutions, pharmaceutical companies, and biotechnology firms worldwide. With growing emphasis on precision medicine and regenerative therapies, cell reprogramming technologies are increasingly being integrated into drug discovery pipelines, disease modeling platforms, and potential therapeutic interventions for previously untreatable conditions. The convergence of advanced gene editing technologies, improved reprogramming protocols, and enhanced understanding of cellular plasticity mechanisms has positioned this market at the forefront of next-generation medical innovations, promising to reshape treatment paradigms across multiple therapeutic areas.

Market Dynamics

The global cell reprogramming market is propelled by several compelling drivers that collectively fuel its robust expansion trajectory. The increasing prevalence of chronic diseases, genetic disorders, and age-related conditions creates substantial demand for innovative therapeutic approaches that cell reprogramming technologies uniquely address. Growing investments in regenerative medicine research, coupled with supportive government funding initiatives and favorable regulatory frameworks, significantly accelerate market development. Technological advancements in reprogramming methodologies, including non-integrative approaches and chemically-defined protocols, enhance efficiency while reducing safety concerns, thereby expanding commercial viability.

The pharmaceutical industry's intensifying focus on personalized medicine and patient-specific therapeutic solutions drives adoption of iPSC-based drug screening and toxicity testing platforms. However, market growth faces notable restraints including complex regulatory pathways for cell-based therapies, substantial technical challenges in achieving consistent reprogramming efficiency, and significant cost barriers associated with establishing specialized laboratory infrastructure. Ethical considerations surrounding stem cell research, along with limited standardization across reprogramming protocols, create additional market entry barriers. Safety concerns regarding genomic instability and tumorigenic potential of reprogrammed cells continue to pose regulatory and commercial challenges. Nevertheless, emerging opportunities present substantial growth potential, particularly through expanding applications in disease modeling, drug discovery acceleration, and development of off-the-shelf cellular therapies. Strategic partnerships between biotechnology companies and pharmaceutical giants facilitate technology transfer and commercialization pathways. Growing adoption in emerging markets, coupled with increasing awareness of regenerative medicine benefits, creates new revenue streams and market expansion opportunities for industry participants.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cell reprogramming market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Thermo Fisher Scientific, Merck KGaA, Takara Bio Inc, Lonza Group, FUJIFILM Cellular Dynamics, StemCell Technologies, REPROCELL Inc, Astellas Pharma, Fate Therapeutics, Cynata Therapeutics, Pluri Inc, ViaCyte Inc, BlueRock Therapeutics, Century Therapeutics, and Editas Medicine.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global cell reprogramming market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell reprogramming market.

Market Segmentation

• Product Insights (Revenue, USD Mn, 2021 - 2033)
• Instruments
  • Reprogramming Workstations
  • Bioreactors
  • Microscopes
  • Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
  • Incubators and Biostorage (COa,, incubators, cryostorage units)
  • Centrifuges (Cell harvesting, processing, etc.)
• Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
• Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
• Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
• Cell Type Insights (Revenue, USD Mn, 2021 - 2033)
• Somatic Cells
• Embryonic Stem Cells
• Adult Stem Cells
• Cancer Stem Cells
• Mesenchymal Stem Cell
• Source of Cells Insights (Revenue, USD Mn, 2021 - 2033)
• Human Cells
• Animal Cells
• Technology Insights (Revenue, USD Mn, 2021 - 2033)
• Sendai Virus-based Reprogramming
• mRNA Reprogramming
• Episomal Reprogramming
• Small Molecule-based Reprogramming
• CRISPR or Cas9-based Reprogramming
• Other Reprogramming Technologies
• Application Insights (Revenue, USD Mn, 2021 - 2033)
• Stem Cell Research
• Disease Modeling
• Toxicology Testing
• Drug Screening
• Regenerative Medicine
• End User Insights (Revenue, USD Mn, 2021 - 2033)
• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Contract Research Organizations (CROs)
• Government and Non-profit Organizations
• Others (Academic and Research Institutions, etc.)
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Thermo Fisher Scientific
• Merck KGaA
• Takara Bio Inc
• Lonza Group
• FUJIFILM Cellular Dynamics
• StemCell Technologies
• REPROCELL Inc
• Astellas Pharma
• Fate Therapeutics
• Cynata Therapeutics
• Pluri Inc
• ViaCyte Inc
• BlueRock Therapeutics
• Century Therapeutics
• Editas Medicine

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Cell Reprogramming Market, By Product
  • Global Cell Reprogramming Market, By Cell Type
  • Global Cell Reprogramming Market, By Source of Cells
  • Global Cell Reprogramming Market, By Technology
  • Global Cell Reprogramming Market, By Application
  • Global Cell Reprogramming Market, By End User
  • Global Cell Reprogramming Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Cell Reprogramming Market, By Product, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Instruments
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
    • Reprogramming Workstations
      • Bioreactors
      • Microscopes
      • Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
      • Incubators and Biostorage (COa,, incubators, cryostorage units)
      • Centrifuges (Cell harvesting, processing, etc.)
• Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Cell Reprogramming Market, By Cell Type, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Somatic Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Embryonic Stem Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Adult Stem Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Cancer Stem Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Mesenchymal Stem Cell
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Cell Reprogramming Market, By Source of Cells, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Human Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Animal Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Cell Reprogramming Market, By Technology, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Sendai Virus-based Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• mRNA Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Episomal Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Small Molecule-based Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• CRISPR or Cas9-based Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Other Reprogramming Technologies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

8. Global Cell Reprogramming Market, By Application, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Stem Cell Research
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Disease Modeling
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Toxicology Testing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Drug Screening
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Regenerative Medicine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

9. Global Cell Reprogramming Market, By End User, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Pharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Contract Research Organizations (CROs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Goverment and Non-profit Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Others (Academic and Research Institutions, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

10. Global Cell Reprogramming Market, By Region, 2021 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takara Bio Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lonza Group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FUJIFILM Cellular Dynamics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• StemCell Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• REPROCELL Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fate Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cynata Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pluri Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ViaCyte Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BlueRock Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Century Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Editas Medicine
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us